K
Kelly Logue
Researcher at Wilmington University
Publications - 5
Citations - 576
Kelly Logue is an academic researcher from Wilmington University. The author has contributed to research in topics: Virus & Efavirenz. The author has an hindex of 5, co-authored 5 publications receiving 554 citations.
Papers
More filters
Journal ArticleDOI
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
Jeffrey W. Corbett,Soo S. Ko,James D. Rodgers,Lisa A. Gearhart,Nicholas Andrew Magnus,Lee T. Bacheler,Sharon Diamond,Susan Jeffrey,Ronald M. Klabe,Beverly C. Cordova,Sena Garber,Kelly Logue,George L. Trainor,Paul Anderson,Susan Erickson-Viitanen +14 more
TL;DR: The increased potency of these NRTIs is combined with favorable plasma serum protein binding as demonstrated by improvements in the percent free drug in human plasma when compared to efavirenz.
Journal ArticleDOI
Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy
Lee T. Bacheler,Susan Jeffrey,George J. Hanna,Richard T. D'Aquila,Lany Wallace,Kelly Logue,Beverly C. Cordova,Kurt Hertogs,Brendan Larder,Renay Buckery,David C. Baker,Karen Gallagher,Helen Scarnati,Radonna Tritch,Chris Rizzo +14 more
TL;DR: Variant strains of HIV-1 constructed by site-directed mutagenesis confirmed the role of K103N, G190S, and Y188L substitutions in reduced susceptibility to efavirenz.
Journal ArticleDOI
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
G. V. De Lucca,U. T. Kim,Jing Liang,Beverly C. Cordova,Ronald M. Klabe,Sena Garber,Lee T. Bacheler,Gilbert N. Lam,Matthew R. Wright,Kelly Logue,Susan Erickson-Viitanen,Soo S. Ko,George L. Trainor +12 more
TL;DR: Using the structural information gathered from the X-ray structures of various cyclic urea/HIVPR complexes, the efforts concentrated on using an indazole as one of the P2 substituents since this group imparted enzyme potency as well as translation into excellent antiviral (IC90) potency.
Journal ArticleDOI
Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
David A. Nugiel,Kim Jacobs,Lyndon A. M. Cornelius,Chong-Hwan Chang,Prabhakar K. Jadhav,Edward R. Holler,Ronald M. Klabe,Lee T. Bacheler,Beverly C. Cordova,Sena Garber,Carol Reid,Kelly Logue,Lorraine J. Gorey-Feret,Gilbert N. Lam,Susan Erickson-Viitanen,Steven P. Seitz +15 more
TL;DR: Several novel P1/P1' substituents that can replace the characteristic benzyl P1 or P1' moiety of the cyclic urea based HIV protease inhibitor series provide 5-10-fold improvements in binding affinity compared to the unsubstituted benzyl analogs.
Journal ArticleDOI
DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants
Robert F. Kaltenbach,George L. Trainor,Getman Daniel P,Greg D. Harris,Sena Garber,Beverly C. Cordova,Lee T. Bacheler,Susan Jeffrey,Kelly Logue,Pamela Cawood,Ronald M. Klabe,Sharon Diamond,Marc Davies,Joanne Saye,Janan Jona,Susan Erickson-Viitanen +15 more
TL;DR: Two compounds resulting from studies are potent and selective inhibitors of HIV protease with IC90s for wild-type HIV-1 of 4 to 40 nM, and a fivefold or smaller loss in potency toward mutant variants with three to five amino acid substitutions.